Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Pan Afr Med J ; 23: 149, 2016.
Artículo en Francés | MEDLINE | ID: mdl-27279974

RESUMEN

Panniculitis is a rare cutaneous manifestation of dermatomyositis (DM). The appearance of panniculitis during treatment with methotrexate (MTX) is exceptional and has only been described in 3 cases. We report a case of a 50-year-old woman suffering from DM since 1997 who was treated with corticosteroids showing favorable clinical and biological evolution. When a relapse occurred 2 years later, she was treated with higher-dose of corticosteroids in combination with a 7,5 mg weekly dose of methotrexate. The evolution was rapidly favorable. Eighteen months later, the patient had multiple subcutaneous nodules on limbs and buttocks. Anatomopathological examination showed panniculitis. There was no evidence supporting progression in DM. Prednisone dose was increased to 0.5 mg/kg/day, always in combination with MTX, without any clear signs of improvement. MTX treatment was stopped and the cutaneous lesions completely disappeared in 2 months without any relapse. This objective response lasted for 42 months. Our observation is particular given the occurrence of panniculitis in a patient undergoing treatment for dermatomyositis with methotrexate and illustrates the difficulties in the diagnosis. This entity must be known despite its exceptional nature since cutting off MTX treatment generally induces the disappearance of subcutaneous nodules.


Asunto(s)
Dermatomiositis/complicaciones , Metotrexato/uso terapéutico , Paniculitis/etiología , Prednisona/uso terapéutico , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/uso terapéutico , Dermatomiositis/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Femenino , Glucocorticoides/administración & dosificación , Glucocorticoides/uso terapéutico , Humanos , Metotrexato/administración & dosificación , Persona de Mediana Edad , Paniculitis/diagnóstico , Paniculitis/tratamiento farmacológico , Prednisona/administración & dosificación , Recurrencia
2.
Int J Rheum Dis ; 16(5): 539-46, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24164841

RESUMEN

AIM: Clinical features of systemic lupus erythematosus (SLE) have been described from different geographical regions around the world. However, data from North African countries, including Tunisia, are scarce. METHODS: The aim of this retrospective multicenter study was to analyze demographic, clinical, laboratory features and outcome of SLE in Tunisia throughout 14 Departments of Internal Medicine and to compare them with those of other ethnic and geographic groups. RESULTS: Seven hundred and forty-nine cases of SLE were recorded (American College of Rheumatology criteria) during a 17-year period (1989-2006). They were 676 women and 73 men with an average age at SLE onset of approximately 30.66 years. Our Tunisian patients were characterized by a high frequency of photosensitivity (67.6%), malar rash (68.7%), renal involvement (49.5%) and anti-Sm antibodies (44.8%). Infections were the main complications. Fifty-six (7.5%) patients died during the study period. CONCLUSION: Potential limitations and biases in our study need discussion. Specific recruitment of patients in tertiary referral centers may be the source of selection bias and adding to the frequency of moderate or even severe diseases. The therapeutic management and outcome monitoring were heterogeneous due to the fact that patients were evaluated by different doctors. However, this study remains the most representative of Tunisian SLE patients recruited from all parts of Tunisia.


Asunto(s)
Lupus Eritematoso Sistémico/epidemiología , Adolescente , Adulto , Edad de Inicio , Anciano , Autoanticuerpos/sangre , Niño , Preescolar , Femenino , Humanos , Lupus Eritematoso Cutáneo/epidemiología , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/tratamiento farmacológico , Lupus Eritematoso Sistémico/mortalidad , Nefritis Lúpica/epidemiología , Masculino , Persona de Mediana Edad , Trastornos por Fotosensibilidad/epidemiología , Pronóstico , Estudios Retrospectivos , Factores de Tiempo , Túnez , Adulto Joven , Proteínas Nucleares snRNP/inmunología
3.
Eur J Intern Med ; 23(4): 347-9, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22560383

RESUMEN

BACKGROUND: Many researchers have tried to investigate the association of HLA-B51 with the severity and the clinical features of BD with conflicting results. METHODS: We aimed at investigating the association of HLA-B51 with demographical and clinical manifestations as well as the severity of BD, by studying 178 native Tunisian BD patients, fulfilling the International Study group criteria for the BD classification recruited from the Department of Internal Medicine, Rabta Hospital in Tunis and compared with 125 native Tunisian healthy age and sex matching volunteers. RESULTS: According to our findings, the frequency of HLAB 51 was significantly higher in BD patients than in controls (p<0.001). Positive pathergy test (PPT) (p = 0.01) and retinal vasculitis (p = 0.045), were significantly more frequent in HLA B51(+) patients, while the frequency of arterial aneurysms (p = 0.009) and neurological involvement, especially the parenchymal involvement (p<0.001), were significantly and clearly higher in HLA B51(-) patients. The patients without HLA B51 had a significantly less severe disease (p = 0.001). Discussion/conclusion We conclude that HLA B51 is a predisposing marker for BD in our population as in most ethnic groups. It seems to be associated with a subgroup of BD patients characterized by a higher frequency of ocular involvement and PPT, but a lower frequency of arterial aneurysm and neurological involvement, and a less severe disease course.


Asunto(s)
Síndrome de Behçet/genética , Predisposición Genética a la Enfermedad , Antígeno HLA-B51/genética , Adulto , Síndrome de Behçet/diagnóstico , Síndrome de Behçet/inmunología , Femenino , Antígeno HLA-B27/inmunología , Antígeno HLA-B51/inmunología , Haplotipos , Humanos , Masculino , Túnez , Adulto Joven
4.
Case Rep Med ; 2012: 486421, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22474456

RESUMEN

We describe a case of a 40-year-old woman who presented with ecchymoses of the right leg and who was found to have lobular panniculitis in biopsy due to Munchausen's Syndrome.

5.
Mediators Inflamm ; 13(4): 247-53, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15545055

RESUMEN

BACKGROUND: Peripheral blood CD8+ T cells expressing interferon gamma and interleukin-4 (IL-4), and lacking CD28 molecules, were responsible for the dynamic interplay between peripheral blood and inflammatory sites. INTRODUCTION: The aim of the current study was to define in Behçet's disease (BD), CD8+ T-cell subsets using CD28 and CD11b monoclonal antibodies, and the characterization of the Tc1/Tc2 ratio and perforin expression. METHODS: Flow cytometry was used for intracytoplasmic cytokines and perforin expression. Effector cells were investigated by adhesion of CD8+ T cells to human microvascular endothelial cells and by chemotaxis using beta-chemokine. RESULTS: Interferon-gamma-producing CD8+ T cells in active and remission BD patients were increased, which induce a significant increase of the Tc1:Tc2 ratio in BD. CD8(+)CD28(-)CD11b+ T cells were found to be more expanded in BD patients than in age-matched healthy controls. The expression of CD11b molecules in active BD allowed to CD8(+)CD28+/CD8(+)CD28- subsets to adhere to human microvascular endothelial cells, with more efficiency in BD. Using MIP-1alpha, we observed that the migratory process of CD28(-)CD11b(+) is more important in BD. CD28(-)CD11b+ exhibited an increased perforin expression in BD patients. CONCLUSION: Taken together these results suggest the presence of immune activation, probably in response to a profound inflammation affecting BD patients. The physiopathological significance of these results were toward autoimmune diseases and/or infectious process.


Asunto(s)
Síndrome de Behçet/patología , Linfocitos T CD8-positivos/patología , Subgrupos de Linfocitos T/patología , Glándulas Suprarrenales/irrigación sanguínea , Adulto , Anticuerpos Monoclonales , Síndrome de Behçet/fisiopatología , Antígeno CD11b/metabolismo , Antígenos CD28/metabolismo , Linfocitos T CD8-positivos/metabolismo , Capilares , Adhesión Celular , Células Cultivadas , Quimiotaxis de Leucocito , Citocinas/metabolismo , Células Endoteliales , Femenino , Humanos , Membranas Intracelulares/metabolismo , Masculino , Glicoproteínas de Membrana/metabolismo , Persona de Mediana Edad , Perforina , Proteínas Citotóxicas Formadoras de Poros , Subgrupos de Linfocitos T/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA